{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-256934","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.427499+00:00","generated_at":"2026-06-09T23:40:05.725502+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Zymeworks announces director Lota Zoth will not seek re-election; nominates oncology leader Nancy Davidson to board","bullets":["Director Lota Zoth not standing for re-election at Dec. 7, 2023 annual meeting; will continue as lead independent director until term ends.","Board nominates Dr. Nancy Davidson for election; if elected, she serves as Class II director with term through 2026 annual meeting.","Davidson is EVP for Clinical Affairs at Fred Hutchinson Cancer Center, past president of ASCO and AACR, bringing deep oncology expertise.","If elected, Davidson will receive an initial stock option grant for 50,000 shares under standard non-employee director compensation.","Company is targeting zanidatamab approval/commercialization and five IND filings before end of 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-256934","json":"https://secwatch.observer/filing/0001193125-23-256934.json","markdown":"https://secwatch.observer/filing/0001193125-23-256934.md","text":"https://secwatch.observer/filing/0001193125-23-256934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523256934/0001193125-23-256934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523256934/d569983d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:40:05.725502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d42f95c783","claim":"Lota Zoth departed as Director at Zymeworks Inc..","evidence_excerpt":"Ms. Lota Zoth, a member of the Board of Directors (the “Board”) of Zymeworks Inc. (the “Company”) notified the Company of her decision not to stand for re-election to the Board at the Company’s next annual meeting of stockholders to be held on or about December 7, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523256934/0001193125-23-256934-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}